^
    4d
    EAY131-C2: Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2) (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, National Cancer Institute (NCI) | N=35 --> 20 | Trial completion date: Feb 2026 --> Dec 2026
    Enrollment change • Trial completion date
    |
    MET exon 14 mutation
    |
    Xalkori (crizotinib)
    6d
    CMUH110-REC3-246: Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1 (clinicaltrials.gov)
    P1, N=5, Completed, China Medical University Hospital | Active, not recruiting --> Completed | Trial completion date: Jun 2026 --> Feb 2026
    Trial completion • Trial completion date • IO biomarker
    |
    ALK (Anaplastic lymphoma kinase)
    |
    Opdivo (nivolumab) • Alecensa (alectinib)
    6d
    EAY131-C1: Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1) (clinicaltrials.gov)
    P2, N=44, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Dec 2026
    Trial completion date
    |
    MET amplification
    |
    Xalkori (crizotinib)
    7d
    Clinical Manifestations of Primary CNS T-Cell Lymphoma: A Retrospective Study of Histopathologic, Molecular, and Neuroimaging Features. (PubMed, Neurology)
    Although PCNSTL is exceptionally rare, we identified distinct neuroimaging patterns showing highly aggressive features on MRI but hypometabolic PET imaging, which may assist in identifying future PCNSTL cases. Despite the limited cohort size, our findings suggest that MTX-based chemotherapy with ASCT may translate into favorable outcome. We report on an ALK1-positive PCNSTL case with sustained complete remission after targeted therapy with lorlatinib.
    Retrospective data • Journal
    |
    ALK1 (Activin A Receptor Like Type 1)
    |
    Lorbrena (lorlatinib) • methotrexate
    8d
    Survey of Brigatinib Used To Treat People With Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P=N/A, N=500, Recruiting, Takeda | Trial completion date: Nov 2027 --> Sep 2030 | Trial primary completion date: Nov 2027 --> Sep 2030
    Trial completion date • Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive • ALK fusion
    |
    Alunbrig (brigatinib)
    9d
    Treatment with ensartinib improves postoperative survival in a patient with stage IIB LUAD carrying a rare ALK mutation: case report. (PubMed, Open Life Sci)
    The patient recovered well and was discharged after four postoperative days. During more than four years of follow-up, long-term ensartinib therapy was associated with stable disease without recurrence, offering potential clinical insights for managing LUAD with rare ALK variants.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • TOGARAM2 (TOG Array Regulator Of Axonemal Microtubules 2)
    |
    ALK mutation
    |
    Ensacove (ensartinib)
    13d
    Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion (clinicaltrials.gov)
    P1, N=15, Recruiting, Nationwide Children's Hospital | Active, not recruiting --> Recruiting
    Enrollment open
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ROS1 fusion
    |
    carboplatin • Lorbrena (lorlatinib) • cyclophosphamide
    14d
    Crizotinib attenuates bleomycin-induced pulmonary fibrosis via regulating fibroblast activation. (PubMed, J Thorac Dis)
    Crizotinib could inhibit the PI3K/AKT/mTOR, STAT3 and ERK signaling pathways. Crizotinib might be an emerging medication choice for patients with IPF.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • FN1 (Fibronectin 1) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    Xalkori (crizotinib) • bleomycin
    15d
    Ceritinib Induces Mitochondrial Fragmentation in Thyroid Cancer Cells by Targeting Drp-1. (PubMed, Drug Dev Res)
    Our findings reveal that ceritinib disrupts mitochondrial dynamics via the MCU/calpain/Drp1 axis. This study identifies a previously unreported mechanism for ceritinib in thyroid carcinoma, suggesting a novel therapeutic strategy.
    Journal
    |
    CAPN1 (Calpain 1) • SOD2 (Superoxide Dismutase 2)
    |
    Zykadia (ceritinib)
    16d
    Targeted therapy for ALK-positive histiocytosis masquerading as optic nerve tumor: a case report. (PubMed, Childs Nerv Syst)
    Lorlatinib, a third-generation ALK tyrosine kinase inhibitor, was started which showed significant disease regression at 18-month follow-up. This report highlights the favorable response to targeted ALK inhibition in central nervous system ALK-positive histiocytosis.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • KIF5B (Kinesin Family Member 5B) • CD163 (CD163 Molecule) • TPM3 (Tropomyosin 3)
    |
    ALK positive • ALK fusion
    |
    Lorbrena (lorlatinib)
    16d
    DURABLE: Delayed or Upfront Brain RAdiotherapy in Treatment naïve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements (clinicaltrials.gov)
    P1/2, N=56, Recruiting, Joshua Palmer | Trial completion date: Jan 2027 --> Jun 2027 | Trial primary completion date: Jan 2026 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    ALK positive • ALK rearrangement
    |
    Alecensa (alectinib)
    16d
    Anaplastic Lymphoma Kinase (ALK)-Positive Large B-cell Lymphoma in Children: A Case Report and Review of Literature. (PubMed, Cureus)
    The patient was treated with CHOP chemotherapy, with alectinib added from the second cycle...Notably, neuron-specific enolase levels increased in parallel with disease progression. This case highlights diagnostic challenges related to an unusual clinical presentation and pathological overlap with other hematologic diseases.
    Journal • IO biomarker
    |
    ALK (Anaplastic lymphoma kinase) • CD38 (CD38 Molecule) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • IRF4 (Interferon regulatory factor 4)
    |
    ALK positive • ALK mutation • PTPRC expression
    |
    Alecensa (alectinib)